Scottish Medicines Consortium

Restart meetings on drug approvals. This could potentially not only save the life of people who have other medical conditions other than Covid-19 but can be beneficial to the NHS in terms of financial savings. Delaying drug approvals can mean disease progression which in turn can put more stress on the NHS and it's resources. Earlier treatment must surely be preferable both for patients and the economy.

Drugs for medical conditions improve quality of life. People can contribute back to society and the NHS can potentially make savings.